Citations

Clear

4847 citation(s) found for "Tu, Eric".

White matter hyperintensities: A long‐term consequence of repetitive head impacts?
Alosco, Michael L. , Tuz‐Zahra, Fatima , Balcer, Laura J. , Bernick, Charles , Peskind, Elaine R. , Mariani, Megan, Banks, Sarah J. , Bondi, Mark W. , Delano‐Wood, Lisa , Coleman, Michael J. , Palmisano, Joseph , Martin, Brett, Lin, Alexander , Reiman, Eric M. , Ly, Monica T. , Tripodis, Yorghos , Adler, Charles H. , Au, Rhoda , Barr, William , Wethe, Jennifer V. , Cantu, Robert C. , Dodick, David W. , McClean, Michael D , Mez, Jesse , Koerte, Inga K , Cummings, Jeffrey L. , Shenton, Martha E. , Stern, Robert A. , Bouix, Sylvain

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S16 | Pages: No page available

10.1002/alz.077856 Get It

AbstractBackgroundRepetitive head impacts (RHI) from American football can lead to tau and non‐tau pathologies that might present as white matter hyperintensities (WMH) on FLAIR MRI. In 2022, we published a study in Alzheimer’s & Dementia that examined WMH and their association with risk factors and clinical function in former elite football players. That study will be presented during this symposium along with new unpublished data that used imaging and fluid biomarkers to examine etiological correlates (tau, amyloid, neurodegeneration, axonal injury, neuroinflammation) of WMH in the same cohort.MethodsThe multi‐site DIAGNOSE CTE Research Project recruited 180 football players and 60 asymptomatic males without RHI (“controls”), all 45‐74 years (Table 1). Participants completed MRI, lumbar puncture, and neuropsychological testing. Lesion Segmentation Toolbox estimated FLAIR WMH, FreeSurfer derived total cortical thickness, and a diffusion pipeline derived average global FA. CSF was analyzed for p‐tau181, Aβ1‐42, NfL, and sTREM2. Tobit regressions compared football players (n = 149) and controls (n = 53) on total and regional log‐WMH and estimated the effects of years of football and age of first exposure (AFE) to football on log‐WMH. Linear regressions evaluated log‐WMH and clinical associations in football players. Structural equation modeling (SEM) examined effects between log‐WMH and cortical thickness, FA, and the CSF biomarkers. Analyses accounted for age, race, revised Framingham Stroke Risk Profile (rFSRP), body mass index, APOE ε4, and evaluation site.ResultsAlosco et al. (2022) found older (i.e., 60+) but not younger football players had greater total, frontal, temporal and parietal log‐WMH compared to controls (FDR‐adjusted p‐values<0.05; Table 2). Among older football players, younger AFE was associated with greater log‐WMH (beta = ‐0.13, 95% CI = ‐0.23,‐0.02). Greater log‐WMH corresponded to worse Trails A‐B (beta = ‐4.32, 95% CI = ‐8.59,‐0.05) and List Learning Long Delay scores (beta = ‐0.56, 95% CI = ‐0.93,‐0.19). Subsequent unpublished SEM analyses in football players (Figure 1) showed the following direct effects on log‐WMH: higher rFSRP, higher CSF p‐tau181, lower FA, and reduced cortical thickness. There were no indirect effects. Compared to controls, SEM associations were stronger in football players exception for cortical thickness.ConclusionsFLAIR WMH might have unique imaging characteristics, risk factors, and pathological underpinnings in people exposed to RHI.
Cross‐sectional comparison of the role of tau burden among Down Syndrome Alzheimer disease and autosomal‐dominant Alzheimer disease
Boerwinkle, Anna H. , Henson, Rachel L. , Thippabhotla, Sharmila, Kennedy, James Tyler, Butt, Omar H. , Chen, Charles D., Christian, Bradley T. , Mapstone, Mark , Tudorascu, Dana , Cohen, Annie , Fagan, Anne M. , Price, Julie C. , Schupf, Nicole , Laymon, Charles M. , Krinsky‐McHale, Sharon J. , Lai, Florence , Rosas, H. Diana , Lott, Ira T. , Silverman, Wayne , Chhatwal, Jasmeer P. , Chui, Helena C., Farlow, Martin R. , Graff‐Radford, Neill R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Xiong, Chengjie , Wisch, Julie K. , Gordon, Brian A. , Flores, Shaney , McKay, Nicole S. , Handen, Benjamin L. , Head, Elizabeth , Zammit, Matthew D. , Johnson, Sterling C. , Klunk, William E. , Rafii, Michael S. , O’Bryant, Sid E. , Yassa, Michael A. , Keator, David B. , Hartley, Sigan L. , Zaman, Shahid H. , Lao, Patrick , Brickman, Adam M. , Lee, Joseph H. , Allegri, Ricardo , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Fox, Nick C. , Goate, Alison , Day, Gregory S. , Jucker, Mathias , Lee, Jae‐Hong , Xiong, Chengjie , Martins, Ralph N. , Sánchez‐Valle, Raquel , Schofield, Peter William , Xiong, Chengjie , Schindler, Suzanne E. , Morris, John C. , Karch, Celeste M. , Hassenstab, Jason , Benzinger, Tammie L.S. , McDade, Eric , Bateman, Randall J. , Ances, Beau M.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S14 | Pages: No page available

10.1002/alz.079102 Get It

AbstractBackgroundAdults with Down Syndrome (DS) develop Alzheimer disease (AD)‐like pathology and dementia as they age. This is attributed to triplication of the amyloid precursor protein gene. Recent work demonstrated that amyloid is elevated in DS and accumulates in a similar topography to autosomal dominant AD (ADAD). Tau accumulation is the second hallmark of AD and may be measured using tau positron emission tomography (PET) imaging. The pattern of tau accumulation remains unknown in DS.MethodIn a cross‐sectional analysis we evaluated amyloid and tau positron emission tomography (PET) in 124 participants with DS (109 cognitively stable, 8 symptomatic, 7 no consensus), 29 ADAD mutation carriers (26 asymptomatic, 3 symptomatic), and 201 cognitively normal non‐mutation carriers (CN). Regional cortical standard uptake value ratios (SUVR) for tau imaging were obtained and compared by cognitive status. Similarly, regional cortical amyloid SUVR were obtained and converted to centiloids. We then compared the magnitude of tau burden as well as spatial spread of tau across groups relative to amyloid burden.ResultCompared to CN, tau PET binding was elevated in participants with (µDS = 2.12 ± 0.22 SUVR, µADAD = 2.52 ± 0.37 SUVR) and without (µDS = 1.24 ± 0.15 SUVR, µADAD = 1.16 ± 0.19 SUVR) cognitive changes. For both groups, tau increased with increasing amyloid (centiloids). In some regions, DS had greater tau burden for a given amyloid level (centiloids) (Figure 1). There was increased spatial distribution of tau throughout the brain for participants with DS compared to CN. In contrast, tau burden was more focal in participants with ADAD with tau primarily elevated in posterior regions (Figure 2).ConclusionWhile tau burden was higher with symptomatic disease for both groups, significant differences existed in the overall amount and spatial spread. Tau spread was greatest in participants with DS and more diffuse compared to ADAD. These results indicate a substantial tau burden is present in DS, and suggest not only anti‐amyloid but also tau‐reducing agents should be considered for treating cognitive decline in adults with DS.
Refinement of Neurofilament light Dynamics in CSF and Blood for familial Alzheimer’s Disease
Hofmann, Anna, Haesler, Lisa M., Preische, Oliver, Gräber‐Sultan, Susanne, Obermüller, Ulrike , Vöglein, Jonathan , Laske, Christoph , Fitzpatrick, Colleen , Levin, Raina, Chen, Charles D., Chui, Helena C., Fagan, Anne M. , Farlow, Martin R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Xiong, Chengjie , Graff‐Radford, Neill R. , Chhatwal, Jasmeer P. , Vöglein, Jonathan , Xiong, Chengjie , Joseph‐Mathurin, Nelly , Cruchaga, Carlos , Goate, Alison , Allegri, Ricardo , Benzinger, Tammie L.S. , Berman, Sarah , Chui, Helena C. , Fox, Nick C. , Day, Gregory S. , Hassenstab, Jason , Jack, Clifford R. , Lee, Jae‐Hong , Levey, Allan I. , Martins, Ralph N. , Noble, James M. , Sperling, Reisa Anne , Rosa-Neto, Pedro , Sánchez‐Valle, Raquel , Schofield, Peter R. , Xiong, Chengjie , Karch, Celeste M. , Gordon, Brian A. , Morris, John C. , McDade, Eric , Bateman, Randall J. , Jucker, Mathias , Schultz, Stephanie A.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S14 | Pages: No page available

10.1002/alz.078802 Get It

AbstractBackgroundDisease‐modifying therapies for Alzheimer’s Disease (AD) are likely most beneficial when initiated in the pre‐symptomatic phase. To track success of such interventions fluid biomarkers became instrumental, with neurofilament light chain (NfL) showing particular promise. We previously reported that serum NfL increases in pre‐symptomatic phases of familial (autosomal‐dominantly inherited) AD (fAD) and that within‐person rate‐of‐change in NfL is an earlier predictor of fAD symptom onset compared to cross‐sectional levels. The aim of the study at hand was to extend these initial findings in a larger cohort.MethodParticipants enrolled in the Dominantly Inherited Alzheimer Network (DIAN) with matched cross‐sectional and longitudinal cerebrospinal fluid (CSF; n = 962) as well as plasma (n = 1294) samples were used. NfL measurements have been performed on the SIMOA platform using commercially available assay‐kits. To investigate the influence of physiological factors independent from AD, we first analyzed whether age and body mass index (BMI) could account for observed variation in inter‐individual CSF and plasma NfL levels considering non‐carrier family‐members (NC) as a healthy control group. Next, utilizing estimated years to symptom onset (EYO) and previously published methods (Preische et al., 2019), we determined the point in disease course when baseline and longitudinal CSF and plasma NfL concentrations started to increase in mutation carriers (MC) relative to NC, after adjusting for age and BMI.ResultOur results reveal a tight correlation of CSF and blood NfL values within MC as well as NC (figure 1A‐B). However, within NC, after correction for age and BMI, some unexplained variability remained (figure 1C). Further, a decrease of the NfL plasma/CSF ratio over age was found after correcting for BMI (figure 1D). The discrimination of MC from NC was equally good for plasma compared to CSF, being possible on the group level as early as around ‐15 to almost ‐20 EYO depending on the modelling (figure 2).ConclusionOur results support plasma equivalently to CSF NfL as a clinically useful biomarker to longitudinally track neurodegeneration in fAD. The systemic factors influencing physiological NfL values in blood should be investigated in future studies to further improve interpretation of this biomarker.
Leveraging Large‐scale CSF Proteomics to identify Disease Progression Biomarkers in Autosomal Dominant Frontotemporal Lobar Degeneration
Staffaroni, Adam M. , Heuer, Hilary W. , Wise, Amy B. , Forsberg, Leah K. , Kramer, Joel H. , Li, Jingyao , Sivasankaran, Rajeev , Worringer, Katie, Rosen, Howard J. , Boxer, Adam L. , Casaletto, Kaitlin B. , Saloner, Rowan , Dammer, Eric B. , Johnson, Erik C. B. , Paolillo, Emily W. , Miller, Bruce L. , Loureiro, Joseph , Worringer, Katie, Boeve, Bradley F. , Rojas, Julio C.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S14 | Pages: No page available

10.1002/alz.073417 Get It

AbstractBackgroundThe pathophysiological mechanisms driving frontotemporal lobar degeneration (FTLD) disease progression and corresponding biomarkers that capture these changes are not fully understood. We leveraged high‐throughput proteomics to identify networks of co‐expressed CSF proteins and candidate biomarkers for prediction of disease progression in adults with autosomal dominant FTLD mutations.Method113 adults carrying autosomal dominant FTLD mutations (C9orf72/GRN/MAPT) and 38 noncarrier controls from the ALLFTD consortium completed baseline lumbar puncture and longitudinal neuropsychological testing. CSF was assayed for SOMAmer proteomics on SOMAscan® v3.0 (4,140 proteins). Network analysis identified weighted protein co‐expression modules, which were annotated via gene ontology and cell‐type enrichment analysis. Disease age estimates that capture proximity to symptom onset were derived from a Bayesian disease progression model incorporating genotype‐specific clinical (cognition, CDR®+NACC FTLD) and biomarker (brain volume, plasma NfL) information. At baseline, local‐weighted regression examined module z‐scores (based on mean/SD of module levels [first principal component] in noncarriers) in relation to disease age. Longitudinal linear mixed‐effects models examined global cognitive trajectories in relation to baseline module z‐scores, as well as individual proteins within prognostic modules.ResultNetwork analysis identified 32 CSF protein co‐expression modules (37 to 223 proteins/module). 16 modules showed mutation‐related deviations from noncarriers. Deviations in ion transport, neurodevelopmental, metabolic, and transcriptional modules occurred several decades before estimated symptom onset (disease age: ‐30 to ‐20 years) and persisted across disease age. Deviations in neuroinflammatory and ubiquitination/autophagy modules occurred ∼10 years before estimated symptom onset. Sharp deviations in RNA binding, protein phosphorylation, neurogenesis, synaptic function, and lysosomal modules occurred near symptom onset (disease age: ‐1 to 4 years). Baseline synaptic and neurogenesis modules were the strongest prognosticators of cognitive decline (module x time: bs>.10, ps<.05). Within these modules, individual proteins with stronger intramodular connectivity exhibited stronger associations with cognitive decline (e.g., synaptic/transmembrane module: r = .40, p = 2.85e‐6; e.g., EPHA5, LRRTM2).ConclusionLarge‐scale analysis of the CSF proteome reveals a biologically‐diverse landscape of protein networks associated with presymptomatic and symptomatic stages of autosomal dominant FTLD. Synaptic and neuron‐enriched protein networks exhibited prodromal deviations that forecasted incipient cognitive decline. ‘Hub’ proteins derived from these affected networks warrant further validation as candidate biomarkers for early FTLD disease progression.
Structural variants in Lewy body dementia and frontotemporal dementia spectrum
Ding, Jinhui , Rasheed, Memoona, Walton, Ronald L., Brand, Harrison , Zhao, Xuefang , Dewan, Ramita , Solaiman, Sultana , Dawson, Ted M. , Albert, Marilyn S. , Pletnikova, Olga, Troncoso, Juan C. , Masellis, Mario, Keith, Julia , Resnick, Susan M. , Ryten, Mina , Hardy, John , Mazzini, Letizia , Moglia, Cristina, Beach, Thomas G. , Graff‐Radford, Neill R. , Jager, Philip L. De , Hardy, John , Kaivola, Karri , Chia, Ruth , Fujita, Masashi , Menon, Vilas , Collins, Ryan L. , Billingsley, Kimberley J. , Talkowski, Michael E. , Ray, Anindita , Jerez, Pilar Álvarez , Malik, Laksh , Rosenthal, Liana S. , Pletniková, Olga , Black, Sandra E. , Ferrucci, Luigi , Tanaka, Toshiko , Topol, Eric J. , Torkamani, Ali , Tienari, Pentti J. , Foroud, Tatiana , Ghetti, Bernardino , Landers, John E. , Morris, Huw R. , D’Alfonso, Sandra , Moglia, Cristina , Calvo, Andrea , Serrano, Geidy E. , Ferman, Tanis J. , Boeve, Bradley F. , Wszołek, Zbigniew K. , Dickson, Dennis W. , Chiò, Adriano , Bennett, David A. , Ross, Owen A. , Dalgard, Clifton L. , Gibbs, J. Raphael , Traynor, Bryan J. , Scholz, Sonja W.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.078497 Get It

AbstractBackgroundStructural variants range from simple loss or gain of genetic material to complex events that restructure entire chromosomes. This heterogeneity coupled with variant size greater than sequencing read‐length makes structural variant mapping from short‐read sequencing data difficult and error‐prone. Consequently, the role of structural variants is poorly explored in many phenotypes, including dementia.MethodWe used the GATK‐SV pipeline that combines four external structural variant mapping algorithms with machine‐learning to build high‐quality consensus structural variant calls. We applied GATK‐SV to short‐read whole‐genome sequencing data of 2,601 frontotemporal dementia‐amyotrophic lateral sclerosis spectrum (FTD/ALS) patients, 2,612 Lewy body dementia (LBD) patients, and 4,132 neurologically unaffected participants.ResultAfter stringent quality‐control, we performed genome‐wide association studies on 2,307 ALS/FTD patients versus 3,677 controls with 4,699 common structural variants and 2,355 LBD patients versus 3,700 controls with 4,889 common structural variants. In the FTD/ALS cohort, we identified well‐known risk variants at the C9orf72 (p‐value = 4.99×10‐18, OR = 14.47, 95% CI = 7.90–26.49) and MAPT loci (p‐value = 3.48×10‐6, OR = 0.77, 95% CI = 0.68–0.86) corroborating the ability of our pipeline to identify disease‐associated structural variants. Moreover, we discovered, replicated, and validated TPCN1 as a novel risk locus for LBD (p‐value = 9.18×10‐6, OR = 1.43, 95% CI = 1.22–1.67). Further, we identified rare exonic variants with known pathogenic or likely pathogenic effects, such as an SNCA gene duplication in LBD and a deletion of exons 1 and 2 in CHCHD10 in FTD/ALS. We additionally observed structural variants in regulatory regions, e.g. a deletion of a key PSEN2 enhancer, which resulted in an approximate 0.70 fold‐change in PSEN2 expression in LBD. Finally, we built an interactive web app where structural variants can be visualized and explored (https://ndru-ndrs-lng-nih.shinyapps.io/non_ad_dementias_sv_app/).ConclusionCommon and rare structural variants play a role in LBD and FTD/ALS. Our structural variant resource is publicly available and can be used to further explore the role of structural variants in LBD and FTD/ALS.
Flortaucipir tau PET findings from former professional and college American football players in the DIAGNOSE CTE research project
Protas, Hillary , Luo, Ji , Alosco, Michael L. , Balcer, Laura J. , Bernick, Charles , Banks, Sarah J. , Coleman, Michael J. , McKee, Ann C. , Daneshvar, Daniel H. , Palmisano, Joseph , Peskind, Elaine R. , Wethe, Jennifer V. , Rabinovici, Gil D. , Johnson, Keith A. , Shenton, Martha E. , Reiman, Eric M. , Rabinovici, Gil D , Wethe, Jennifer V , Daneshvar, Daniel H , Shenton, Martha E , Su, Yi , Chen, Kewei , Adler, Charles H. , Au, Rhoda , Barr, William , Dodick, David W. , Katz, Douglas I. , Marek, Kenneth , McClean, Michael D , Mez, Jesse , II, Robert W. Turner , Tripodis, Yorghos , Cummings, Jeffrey L. , Stern, Robert A.

Mayo Clinic

Alzheimer's & Dementia | December 22, 2023 | Volume: 20 | Issue: 3 | Pages: 1827-1838

10.1002/alz.13602 | PMID 38134231 Get It

AbstractINTRODUCTIONTau is a key pathology in chronic traumatic encephalopathy (CTE). Here, we report our findings in tau positron emission tomography (PET) measurements from the DIAGNOSE CTE Research Project.METHODWe compare flortaucipir PET measures from 104 former professional players (PRO), 58 former college football players (COL), and 56 same‐age men without exposure to repetitive head impacts (RHI) or traumatic brain injury (unexposed [UE]); characterize their associations with RHI exposure; and compare players who did or did not meet diagnostic criteria for traumatic encephalopathy syndrome (TES).RESULTSSignificantly elevated flortaucipir uptake was observed in former football players (PRO+COL) in prespecified regions (p < 0.05). Association between regional flortaucipir uptake and estimated cumulative head impact exposure was only observed in the superior frontal region in former players over 60 years old. Flortaucipir PET was not able to differentiate TES groups.DISCUSSIONAdditional studies are needed to further understand tau pathology in CTE and other individuals with a history of RHI.
Sex differences in brain atrophy in dementia with Lewy bodies
Oltra, Javier , Habich, Annegret , Nedelská, Zuzana , Przybelski, Scott A. , Diaz‐Galvan, Patricia , Lowe, Val J. , Oppedal, Ketil , Philippi, Nathalie , Blanc, Frédéric , Barkhof, Frederik , Padovani, Alessandro , Massa, Federico , Kramberger, Milica G. , Snædal, Jón , Walker, Zuzana , Antonini, Angelo , Segura, Bàrbara , Westman, Eric , Kantarci, Kejal , Antonini, Angelo , Walker, Zuzana , Nedelska, Zuzana , Westman, Eric , Kantarci, Kejal , Barkhof, Frederik , Habich, Annegret , Diaz-Galvan, Patricia , Padovani, Alessandro , Massa, Federico , Segura, Barbara , Schwarz, Christopher G. , Inguanzo, Anna , González, Maria Camila , Lemstra, Afina W. , Hort, Jakub , Rektorová, Irena , Bonanni, Laura , Taylor, John‐Paul , Dierks, Thomas , Junqué, Carme , Boeve, Bradley F. , Aarsland, Dag , Ferreira, Daniel

Mayo Clinic

Alzheimer's & Dementia | December 22, 2023 | Volume: 20 | Issue: 3 | Pages: 1815-1826

10.1002/alz.13571 | PMID 38131463 Get It

Abstract INTRODUCTION Sex influences neurodegeneration, but it has been poorly investigated in dementia with Lewy bodies (DLB). We investigated sex differences in brain atrophy in DLB using magnetic resonance imaging (MRI). METHODS We included 436 patients from the European‐DLB consortium and the Mayo Clinic. Sex differences and sex‐by‐age interactions were assessed through visual atrophy rating scales ( n = 327; 73 ± 8 years, 62% males) and automated estimations of regional gray matter volume and cortical thickness ( n = 165; 69 ± 9 years, 72% males). RESULTS We found a higher likelihood of frontal atrophy and smaller volumes in six cortical regions in males and thinner olfactory cortices in females. There were significant sex‐by‐age interactions in volume (six regions) and cortical thickness (seven regions) across the entire cortex. DISCUSSION We demonstrate that males have more widespread cortical atrophy at younger ages, but differences tend to disappear with increasing age, with males and females converging around the age of 75. Highlights Male DLB patients had higher odds for frontal atrophy on radiological visual rating scales. Male DLB patients displayed a widespread pattern of cortical gray matter alterations on automated methods. Sex differences in gray matter measures in DLB tended to disappear with increasing age.
Supercharging collaboration for bipolar research—Breakthrough discoveries for thriving with bipolar disorder (BD2)
Altimus, Cara M. , Baxi, Emily G. , Frye, Mark A. , Nestler, Eric J. , Pham, Dániel , Burdick, Katherine E. , Burdick, K E

Mayo Clinic

Bipolar Disorders | December 21, 2023 | Volume: 25 | Issue: 8 | Pages: 619-623

10.1111/bdi.13398 | PMID 38127002 Get It

Incidence of injury and illness among paediatric Team USA athletes competing in the 2020 Tokyo and 2022 Beijing Olympic and Paralympic Games
Post, Eric G. , Anderson, Travis , Shilt, Jeffrey S. , Dugan, Eric L. , Clark, Stephanie C., Larson, Emily G., Noble-Taylor, Kayle E, Donaldson, Amber , Finnoff, Jonathan T. , Donaldson, Amber T , Finnoff, Jonathan T , Adams, William M , Anderson, Travis , Noble-Taylor, Kayle E., Robinson, David M. , Adams, William M.

Mayo Clinic

BMJ Open Sport & Exercise Medicine | December 20, 2023 | Volume: 9 | Issue: 4 | Pages: e001730

10.1136/bmjsem-2023-001730 | PMID 38143720 Get It

Objective To describe the incidence of injuries and illnesses among paediatric Team USA athletes competing in the Tokyo 2020 Olympic and Paralympic Games, and the 2022 Beijing Olympic and Paralympic Games. Methods An electronic medical record system documented all injuries and illnesses that occurred while competing in the four Games periods. Incidence (IR) with 95% CI per 1000 athlete days were calculated for both injuries and illnesses. Incidence rate ratios (IRR) were calculated to compare injury and illness rates based on age (paediatric vs non-paediatric) sex, Games period and sport type. Results Two hundred paediatric athletes (age range, 15–21 years) competed across the four Games periods, representing 16.1% of all Team USA athletes. The overall injury IR (95% CI) was 13.4 (9.8 to 18.1), and the overall illness IR was 5.5 (3.3 to 8.7). There were no differences in incidence between paediatric and non-paediatric athletes for either injury (IRR (95% CI): 0.9 (0.6 to 1.2)) or illness (IRR (95% CI): 0.9 (0.5 to 1.5)). Female paediatric athletes were more likely to sustain an injury compared with male paediatric athletes (IRR (95% CI): 2.4 (1.1 to 5.3)). The most common mechanism of injury was gradual onset (IR, 4.3 (2.3 to 7.2)), and injuries most commonly occurred during practices (IR, 7.0 (4.5 to 10.5)). Conclusion Paediatric athletes account for a substantial proportion of Team USA athletes. It is essential that paediatric sports medicine experts are included in the medical team given that paediatric Team USA athletes are just as likely as their adult teammates to sustain an injury or illness.
Abstract 18629: Discriminative Accuracy of Cha 2 Ds 2 Vasc Score, and Development of Predictive Accuracy Model Using Machine Learning for Ischemic Stroke in Cardiac Amyloidosis
Ullah, Waqas , Nair, Abhinav , Warner, Eric, Rajapreyar, Indranee, Alvarez, René , Yaddanapudi, Sridhara , Maurer, Mathew S. , Brailovsky, Yevgeniy , Brailovsky, Yevgeniy , Zahid, Salman , Frisch, Daniel R. , Rajapreyar, Indranee N. , Alkhouli, Mohamad , Maurer, Mathew S

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18629 Get It

Background: Cardiac amyloidosis (CA) in conjunction with atrial fibrillation (AF) presents unique management challenges. CHA2DS2VASc score in these patients is believed to underestimate the risk of ischemic stroke, necessitating a better predictive model in these patients. Methods: Data was obtained from the National Readmission Database (NRD). Outcomes between CA-AF and no-CA-AF were compared using multivariate regression analysis to calculate adjusted odds ratios (aOR). AutoScore; an interpretable machine learning framework, was used to develop a stroke risk prediction model, the predictive accuracy of which was evaluated with an area under the curve (AUC) using the receiver operating characteristic analysis. Results: A total of 11,860,804 (CA-AF 22,687 [0.19%] and no-CA-AF 11,838,117) patients were identified from 2015-2019. The adjusted odds of mortality (aOR 1.41 and 1.29), stroke (aOR 1.78 and 1.74), non-intracranial hemorrhage (aOR 2.10 and aOR 1.85), and intracranial hemorrhage (aOR 14.4 and aOR 4.26) were significantly higher in CA-AF compared with non-CA-AF at both index admission and 30-days, respectively. The CHA 2 DS 2 VASc score had a poor discriminative accuracy for stroke at 30-days in CA-AF (AUC 49%, 95%CI 47%-51%, p=0.54). The machine learning autoscore integrative model revealed that the predictive ability of our newly proposed E-CHADS score (end-stage renal disease (ESRD), congestive heart failure, hypertension, active cancer, dementia, and diabetes mellitus) for 30-day risk of ischemic stroke in CA-AF was excellent (for a cutoff of 52 points random forest score) with an AUC of 80% (95%CI 74%-86%) Conclusion: Cardiac amyloidosis carries a high risk of ischemic stroke that is not accurately predicted by the CHA 2 DS 2 VASc score. Our proposed model (E-CHADS) identifies 3 new variables (ESRD, dementia, and cancer) that have higher discriminative accuracy for ischemic stroke in these patients.